Engineered T cells. Function (growth factor / effector cytokine / effector molecules) Trafficking chemokine receptors



Similar documents
Chapter 18: Applications of Immunology

Multiple Myeloma and Colorectal Cancer

Corporate Medical Policy

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

Manufacturing Cellular Products for International Clinical Trials

T Cell Immunotherapy for Cancer

Valentina Gualato, Ph.D. Process Development Scientist

Chimeric Antigen Receptor T Cell Therapy

Genetic Engineering and Biotechnology

Support structure for genetic material

Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation

The use of monoclonal antibodies in the setting of HSCT

ISCT Stem Cell Translation: Strategies, Best Practices, and Regulatory Considerations September 28, 2010 USP Standards for Cell and Tissue Therapies

A Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy

Ending cancer. Together.

Custom Antibodies & Recombinant Proteins

Human CD4+T Cell Care Manual

On the origin of giant multinuclear Reed-Sternberg cells and the role of CD4 T cells in Hodgkin lymphoma

A Genetic Analysis of Rheumatoid Arthritis

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

Autologous Cellular Therapies. Adrian Gee Center for Cell & Gene Therapy Baylor College of Medicine Production Assistance for Cellular Therapy (PACT)

Document Review: Centers for Medicare and Medical Service (CMS) What Do I Need to Do to Assess Personnel Competency?

Basic Overview of Preclinical Toxicology Animal Models

Stem cells and cellular therapies: from research to clinic. ns,, PhD Faculty of Biology University of Latvia

Comparability of Cord Blood Units

CMC Writing for IND Applications. David H. McKenna, Jr., M.D. University of Minnesota April 10-11, 2007 Workshop

FDA Perspective on the Regulation of TCR/CAR T-cell Products

Microbiology AN INTRODUCTION EIGHTH EDITION

Report series: General cancer information

COMMITTEE FOR HUMAN MEDICINAL PRODUCT (CHMP) DRAFT GUIDELINE ON HUMAN CELL-BASED MEDICINAL PRODUCTS

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Cancer and the immune system: can we beat cancer at its own game?

ELISA BIO 110 Lab 1. Immunity and Disease

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March Antti Vuolanto, COO and co-founder

International Beryllium Conference, Montreal, Canada March 10, 2005

STEM CELL TRANSPLANTS

SMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

STEM CELL FELLOWSHIP

Disclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes

Perspectives on HCT Program Challenges in a Changing Reimbursement Environment The good, the bad, and the ugly

Stem Cell-based Therapies and FDA Regulations

COMMITTEE FOR MEDICINAL PRODUCT FOR HUMAN USE (CHMP) GUIDELINE ON HUMAN CELL-BASED MEDICINAL PRODUCTS

The Four Pillars of Cancer Therapy

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

2) Macrophages function to engulf and present antigen to other immune cells.

Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified)

When B Cells Go Bad: Infection, Inflammation and Chronic B Cell Stimulation

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

Cord Blood Licensure. Session 2C: Advanced Cell Therapies April 11, 2013

Chapter 43: The Immune System

STANDARD OPERATING PROCEDURE

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY

The Need for a PARP in vivo Pharmacodynamic Assay

Basics of Immunology

Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D

Monoclonal Antibody Therapy: Innovations in Cancer Treatment. James Choi ENGL 202C

Activation and effector functions of HMI

Bioinformatics for cancer immunology and immunotherapy

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères Evry Cedex. is involved at each stage of your project

Improved Ex Vivo Expansion of Functional CD34 + Cells Using Stemline II Hematopoietic Stem Cell Expansion Medium

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables

Stem Cell Background Paper

Production of antigens and antibodies in plants: alternative technology?

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Human Umbilical Cord-derived Multipotent Mesenchymal Stromal Cells (huc-msc) Handling Instructions

Diane Kadidlo MT(ASCP) SBB University of Minnesota Joanna Stanson, M.S. University of Pittsburgh

BIOPATENTS IN CHINA. Christopher Shaowei Heather Lin. April 4, 2014, Budapest, Hungary 2014/4/4 NTD IP ATTORNEYS

[DOCKET NO.96N-0002] DRAFT

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

Autoimmunity and immunemediated. FOCiS. Lecture outline

From cells to therapeuticsvivalis. Humalex Fully human antibody discovery platform An integrated therapeutic development offering

HemaCare Corporation Company Overview. Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

Basic Science in Medicine

A Cure for Sickle Cell Anemia and Thalassemia

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

The ethics of stem cell research and treatment

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology

Making the switch to a safer CAR-T cell therapy

In Vivo and In Vitro Screening for Thyroid Hormone Disruptors

Assays to evaluate cell-mediated immunity. Guus Rimmelzwaan Department of Virology Erasmus Medical Center Rotterdam The Netherlands

JOINT COMMISSION INTERNATIONAL ACCREDITATION STANDARDS FOR. 2nd Edition

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

Viral Safety of Plasma-Derived Products

Hematopoietic stem and progenitor cell transplants: regulation and accreditation

Bio-manufacturing of antigens, antibodies and bioresearch materials

Luca Romagnoli, Ph.D. Business Development Manager

Ph.D. in Molecular Medicine

Immunotherapy Concept Turned Reality

Name (print) Name (signature) Period. (Total 30 points)

One of the most important recent developments in cancer treatment has been the ability to harvest stem

EMABling Antibody Production Platform

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview

Uses of Flow Cytometry

Can receive blood from: * I A I A and I A i o Type A Yes No A or AB A or O I B I B and I B i o Type B No Yes B or AB B or O

How To Expand Hematopoietic Stem Cells

Transcription:

Cell Processing Related Issues: Adoptive T cell Immunotherapy Bernard A. Fox Lab of Molecular and Tumor Immunology Robert W. Franz Cancer Research Center Providence Cancer Center Earle A. Chiles Research Institute Portland, Oregon, USA Molecular Microbiology and Immunology Tumor Immunology Focus Group OHSU Knight Cancer Institute Oregon Health and Science University Engineered T cells Marker Function (growth factor / effector cytokine / effector molecules) Trafficking chemokine receptors Resistance Gene Disruption: Steroid receptors (to provide resistance to steroids) TCR or targeting molecule 1

Characterization of procedure and product Source of cells cord blood Peripheral blood stem cells adult PBMC Tumor infiltrating lymphocytes (TIL) Variability of T cell donor Normal healthy donor Immunodefficient Patient Cancer patient Previous chemotherapy or radiation treatments Characterization of procedure and product Collection or recovery method Transport Conditions Apheresis: Cell selection device, density gradients, magnetic beads or FACS Surgery: TIL How many wells of tumor digest initiated (1, 6, 12, 24) Does the number of lymphocytes/ml change the frequency of detecting tumor specific T cells (cloids). Genetic modification and delivery plasmid vs. viral vs.? Optimal point to genetically modify ( Early? Late?) Scale up (cloning plates to 10L bags) Open vs closed culture methods 2

Characterization of procedure and product Generating / expanding tumor specific T cells Stimulation conditions REP Autologous REP Allogeneic (donor screening / eligibility) 21 CFR Part 1271 Eligibility Determination for Donors of Human Cells, Tissues and Cellular and Tissue Based Products (HCT/Ps) and Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue Based Products (HCT/Ps) Beads + Antibodies + Cytokine(s) APC + Antigen + Cytokine(s) + Costim (?) Autologous APC Artificial APC Characterization of procedure and product Maintaining cell phenotype in vivo replication engraftment potential / Memory cells killing capacity or cytokine release / Effector cells 3

Vendor source for material Medium / antibiotics FDA recommends that you do not use beta lactam antibiotics during the manufacturing of a therapeutic product Serum / human AB serum obtained from an approved blood bank and meets all blood donor criteria. Screening sera for desired growth support Growth factors /cytokines cgmp Recombinant available? Transduce feeder or stimulator cells to provide recombinant cytokine Enzymes Trypsin free of porcine parvovirus Triple enzymes : non cgmp (Sigma) vs cgmp Hyaluronidase, Hylenex, Baxter, or Amphadase, Amphastar Pharmaceuticals DNase I recombinant, grade I, Roche Liberase MTF C/T, Roche Monoclonal antibodies Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use Cell separation devices Plastics / availability Optimizing Logistics Culture monitoring metabolites, cell growth, cell cycle fraction.what is limiting to cell expansion? Central processing site(s) and qualification/comparability 4

Characterization of procedure and product Logistic Release/characterization assays; Sterility, Phenotype Potency Develop assay to assess functional property conferred by the genetic modification. Safety Carcinogenetic potential and how to assess Animal In vitro Suicide Vector www.isbtc.org 5

Earle A. Chiles Res. Inst. Christian Poehlein Shawn Jensen Tarsem Moudgil Michael LaCelle Kevin Friedman Chris Twitty James A. Thompson Ulf Petrausch Sachin Puri Levi Maston Sarah Church Edwin Walker Dan Haley Nelson Sanjaun Liliana Gonzalez Tanisha Snyder Andy Weinberg Hong-Ming Hu Lixin Wang Yuhan Li Walter Urba John Smith Brendan Curti Todd Crocenzi Rachel Sanborn Craig Nichols Lynn Glenn Brenda Fisher Theresa Ratzow Tracie Groupe Tracy Kelly Scot Larry Rachel Sautter Erin Sauter Julie Cramer LMU Dominik Ruettinger Hauke Winter Ilka Assmann Rudi Hatz Natasja van den Engel Dolores Schendel Heike Pohla Stephie Grützner Marcus Schlemmer Karl Walter Jauch Xi an Jun Ma L. Si Yili Wang Mayo Clinic AZ Helen Ross Janet Siebert 6